Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483799 | 1.00 | SLC15A2 (0.42) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL4588249 | 0.99 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL2811067 | 0.99 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| Hydrochloric Acid SCHEMBL2199717 | 0.99 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| Hydrochloric Acid SCHEMBL1436163 | 0.99 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL30954680 | 0.99 | SLC15A2 (0.41) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL29590566 | 0.95 | SLC15A2 (0.49) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL20783813 | 0.95 | SLC15A2 (0.49) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL31453803 | 0.95 | SLC15A2 (0.49) | SLC15A2ITGB3ITGA2BCPB2CPB1 | |
| SCHEMBL29888249 | 0.91 | SLC15A2 (0.44) | SLC15A2ITGB3ITGA2BCPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573895-B | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2020-11-24 | — | — | CN | claimed |
| CN-106573895-A | Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof | 特瑞海德公司 | 2017-04-19 | — | — | CN | claimed |
| EP-2793828-B1 | MOISTURIZING COMPOSITION COMPRISING AN AMINOPEPTIDE MIXTURE | UNILEVER PLC (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| EP-2262521-B1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE WITH A GLYCINE MOIETY | BAUSCH & LOMB (US) | 2014-02-26 | — | — | EP | claimed |
| EP-1809720-B1 | FUNCTIONALIZED FLUORESCENT NANOCRYSTALS, AND METHODS FOR THEIR PREPARATION AND USE | LIFE TECHNOLOGIES CORP (US) | 2012-05-02 | — | — | EP | claimed |
| US-7977383-B2 | Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2011-07-12 | — | — | US | claimed |
| EP-2262521-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE | Bausch & Lomb Incorporated (US) | 2010-12-22 | — | — | EP | claimed |
| US-20030215781-A1 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2003-11-20 | — | — | US | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | claimed |
| US-4560515-A | NON-SYMMETRICAL KETENE REACTED WITH A-HYDROXYNITRILE; TERTUARY AMINE CATALYST | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | claimed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| EP-0109681-A2 | process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | SLC15A2 3402/4885ITGB3 3528/4885ITGA2B 2253/4885 |
| US-20030215781-A1 | Protective solutions for organs | GLS, CA1, SI | SLC15A2 457/4885ITGB3 2749/4885ITGA2B 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.